Gilead to Test a Version of Remdesivir That Can Be Inhaled
The American biopharmaceutical company Gilead Sciences will soon start trials of an inhalable version of remdesivir, an antiviral drug that has shown promise as a therapeutic against the coronavirus in early trials, according to a statement released Monday. Remdesivir is currently given intravenously, which restricts its use to hospital settings. “That’s been the limitation” with…
Details